View source: R/BimixedContCont.R
BimixedContCont | R Documentation |
The function BimixedContCont
uses the bivariate mixed-effects approach to estimate trial- and individual-level surrogacy when the data of multiple clinical trials are available. The user can specify whether a full or reduced model should be fitted. See the Details section below. Further, the Individual Causal Association (ICA) is computed.
BimixedContCont(Dataset, Surr, True, Treat, Trial.ID, Pat.ID, Model=c("Full"),
Min.Trial.Size=2, Alpha=.05, T0T1=seq(-1, 1, by=.2), T0S1=seq(-1, 1, by=.2),
T1S0=seq(-1, 1, by=.2), S0S1=seq(-1, 1, by=.2), ...)
Dataset |
A |
Surr |
The name of the variable in |
True |
The name of the variable in |
Treat |
The name of the variable in |
Trial.ID |
The name of the variable in |
Pat.ID |
The name of the variable in |
Model |
The type of model that should be fitted, i.e., |
Min.Trial.Size |
The minimum number of patients that a trial should contain to be included in the analysis. If the number of patients in a trial is smaller than the value specified by |
Alpha |
The |
T0T1 |
A scalar or vector that contains the correlation(s) between the counterfactuals T0 and T1 that should be considered in the computation of |
T0S1 |
A scalar or vector that contains the correlation(s) between the counterfactuals T0 and S1 that should be considered in the computation of |
T1S0 |
A scalar or vector that contains the correlation(s) between the counterfactuals T1 and S0 that should be considered in the computation of |
S0S1 |
A scalar or vector that contains the correlation(s) between the counterfactuals S0 and S1 that should be considered in the computation of |
... |
Other arguments to be passed to the function |
The function BimixedContCont
fits a bivariate mixed-effects model to assess surrogacy (for details, see Buyse et al., 2000). In particular, the following mixed-effects model is fitted:
S_{ij}=\mu_{S}+m_{Si}+(\alpha+a_{i})Z_{ij}+\varepsilon_{Sij},
T_{ij}=\mu_{T}+m_{Ti}+(\beta+b_{i})Z_{ij}+\varepsilon_{Tij},
where i
and j
are the trial and subject indicators, S_{ij}
and T_{ij}
are the surrogate and true endpoint values of subject j
in trial i
, Z_{ij}
is the treatment indicator for subject j
in trial i
, \mu_{S}
and \mu_{T}
are the fixed intercepts for S and T, m_{Si}
and m_{Ti}
are the corresponding random intercepts, \alpha
and \beta
are the fixed treatment effects for S and T, and a_{i}
and b_{i}
are the corresponding random treatment effects, respectively.
The vector of the random effects (i.e., m_{Si}
, m_{Ti}
, a_{i}
and b_{i}
) is assumed to be mean-zero normally distributed with variance-covariance matrix \bold{D}
:
\bold{D}=\left(\begin{array}{cccc}
d_{SS}\\
d_{ST} & d_{TT}\\
d_{Sa} & d_{Ta} & d_{aa}\\
d_{Sb} & d_{Tb} & d_{ab} & d_{bb}
\end{array}\right).
The trial-level coefficient of determination (i.e., R^2_{trial}
) is quantified as:
R_{trial}^{2}=\frac{\left(\begin{array}{c}
d_{Sb}\\
d_{ab}
\end{array}\right)^{'}\left(\begin{array}{cc}
d_{SS} & d_{Sa}\\
d_{Sa} & d_{aa}
\end{array}\right)^{-1}\left(\begin{array}{c}
d_{Sb}\\
d_{ab}
\end{array}\right)}{d_{bb}}.
The error terms \varepsilon_{Sij}
and \varepsilon_{Tij}
are assumed to be mean-zero normally distributed with variance-covariance matrix \bold{\Sigma}
:
\bold{\Sigma}=\left(\begin{array}{cc}\sigma_{SS}\\\sigma_{ST} & \sigma_{TT}\end{array}\right).
Based on \bold{\Sigma}
, individual-level surrogacy is quantified as:
R_{indiv}^{2}=\frac{\sigma_{ST}^{2}}{\sigma_{SS}\sigma_{TT}}.
Note
When the full bivariate mixed-effects approach is used to assess surrogacy in the meta-analytic framework (for details, see Buyse & Molenberghs, 2000), computational issues often occur. Such problems mainly occur when the number of trials is low, the number of patients in the different trials is low, and/or when the trial-level heterogeneity is small (Burzykowski et al., 2000).
In that situation, the use of a simplified model-fitting strategy may be warranted (for details, see Burzykowski et al., 2000; Tibaldi et al., 2003).
For example, a reduced bivariate-mixed effect model can be fitted instead of a full model (by using the Model=c("Reduced")
argument in the function call). In the reduced model, the random-effects structure is simplified (i) by assuming that there is no heterogeneity in the random intercepts, or (ii) by assuming that the covariance between the random intercepts and random treatment effects is zero. Note that under this assumption, the computation of the trial-level coefficient of determination (i.e., R^2_{trial}
) simplifies to:
R_{trial}^{2}=\frac{d_{ab}^{2}}{d_{aa}d_{bb}}.
Alternatively, the bivariate mixed-effects model may be abandonned and the user may fit a univariate fixed-effects model, a bivariate fixed-effects model, or a univariate mixed-effects model (for details, see Tibaldi et al., 2003). These models are implemented in the functions UnifixedContCont
, BifixedContCont
, and UnimixedContCont
).
An object of class BimixedContCont
with components,
Data.Analyze |
Prior to conducting the surrogacy analysis, data of patients who have a missing value for the surrogate and/or the true endpoint are excluded. In addition, the data of trials (i) in which only one type of the treatment was administered, and (ii) in which either the surrogate or the true endpoint was a constant (i.e., all patients within a trial had the same surrogate and/or true endpoint value) are excluded. In addition, the user can specify the minimum number of patients that a trial should contain in order to include the trial in the analysis. If the number of patients in a trial is smaller than the value specified by |
Obs.Per.Trial |
A |
Trial.Spec.Results |
A |
Residuals |
A |
Fixed.Effect.Pars |
A |
Random.Effect.Pars |
A |
Trial.R2 |
A |
Indiv.R2 |
A |
Trial.R |
A |
Indiv.R |
A |
Cor.Endpoints |
A |
D |
The variance-covariance matrix of the random effects (the |
Sigma |
The |
ICA |
A fitted object of class |
T0T0 |
The variance of the true endpoint in the control treatment condition. |
T1T1 |
The variance of the true endpoint in the experimental treatment condition. |
S0S0 |
The variance of the surrogate endpoint in the control treatment condition. |
S1S1 |
The variance of the surrogate endpoint in the experimental treatment condition. |
Wim Van der Elst, Ariel Alonso, & Geert Molenberghs
Burzykowski, T., Molenberghs, G., & Buyse, M. (2005). The evaluation of surrogate endpoints. New York: Springer-Verlag.
Buyse, M., Molenberghs, G., Burzykowski, T., Renard, D., & Geys, H. (2000). The validation of surrogate endpoints in meta-analysis of randomized experiments. Biostatistics, 1, 49-67.
Tibaldi, F., Abrahantes, J. C., Molenberghs, G., Renard, D., Burzykowski, T., Buyse, M., Parmar, M., et al., (2003). Simplified hierarchical linear models for the evaluation of surrogate endpoints. Journal of Statistical Computation and Simulation, 73, 643-658.
UnifixedContCont
, BifixedContCont
, UnimixedContCont
, plot Meta-Analytic
# Open the Schizo dataset (clinial trial in schizophrenic patients)
data(Schizo)
## Not run: #Time consuming (>5 sec) code part
# When a reduced bivariate mixed-effect model is used to assess surrogacy,
# the conditioning number for the D matrix is very high:
Sur <- BimixedContCont(Dataset=Schizo, Surr=BPRS, True=PANSS, Treat=Treat, Model="Reduced",
Trial.ID=InvestId, Pat.ID=Id)
# Such problems often occur when the total number of patients, the total number
# of trials and/or the trial-level heterogeneity
# of the treatment effects is relatively small
# As an alternative approach to assess surrogacy, consider using the functions
# BifixedContCont, UnifixedContCont or UnimixedContCont in the meta-analytic framework,
# or use the information-theoretic approach
## End(Not run)
Add the following code to your website.
For more information on customizing the embed code, read Embedding Snippets.